TY - JOUR
T1 - Associations between outdoor air pollutants and non-viral asthma exacerbations and airway inflammatory responses in children and adolescents living in urban areas in the USA
T2 - a retrospective secondary analysis
AU - National Institute of Allergy and Infectious Disease's Inner City Asthma Consortium
AU - Altman, Matthew C.
AU - Kattan, Meyer
AU - O'Connor, George T.
AU - Murphy, Ryan C.
AU - Whalen, Elizabeth
AU - LeBeau, Petra
AU - Calatroni, Agustin
AU - Gill, Michelle A.
AU - Gruchalla, Rebecca S.
AU - Liu, Andrew H.
AU - Lovinsky-Desir, Stephanie
AU - Pongracic, Jacqueline A.
AU - Kercsmar, Carolyn M.
AU - Khurana Hershey, Gurjit K.
AU - Zoratti, Edward M.
AU - Teach, Stephen J.
AU - Bacharier, Leonard B.
AU - Wheatley, Lisa M.
AU - Sigelman, Steve M.
AU - Gergen, Peter J.
AU - Togias, Alkis
AU - Busse, William W.
AU - Gern, James E.
AU - Jackson, Daniel J.
N1 - Funding Information:
We thank all the participants and their families who took part in this study. We thank Prescott Woodruff, Joshua Boyce, and Stephen Durham for assistance with methodological development, advice, and discussion. The study was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services (contract numbers NO1-AI-25496, NO1-AI-25482, 1UM1AI114271-01, UM2AI117870, and 5UM1AI114271). Additional support was provided by the National Center for Research Resources and National Center for Advancing Translational Sciences, National Institutes of Health (grants NCRR/NIH M01RR00533, NCRR/NIH, 1UL1RR025771, NCRR/NIH UL1RR025741, NCRR/NIH UL1TR000451, UL1RR024982, NCRR/NIH 1UL1RR025780, NCRR/NIH M01RR00071, 1UL1RR024156, NCRR/NIH 5M01RR020359-04, NCRR/NIH UL1RR031988, UL1TRG01422, CTSA Grant UL1RR025741, CTSA Grant UL1TR000150, CTSA Grant UL1TR001422, NIH/NCATS Colorado CTSA UL1 TR002535, NCATS/NIH UL1TR001876, and NIH/CTSA 5UL1TR001425-03). In the ICATA study, Novartis Pharmaceuticals provided the study drug, under a clinical trial agreement with the University of Wisconsin–Madison, Dey Pharma (EpiPens), and SC Johnson (household pest control). None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication. PJG, AT, SMS, and LMW's co-authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency of the US Government.
Funding Information:
We thank all the participants and their families who took part in this study. We thank Prescott Woodruff, Joshua Boyce, and Stephen Durham for assistance with methodological development, advice, and discussion. The study was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services (contract numbers NO1-AI-25496, NO1-AI-25482, 1UM1AI114271-01, UM2AI117870, and 5UM1AI114271). Additional support was provided by the National Center for Research Resources and National Center for Advancing Translational Sciences, National Institutes of Health (grants NCRR/NIH M01RR00533, NCRR/NIH, 1UL1RR025771, NCRR/NIH UL1RR025741, NCRR/NIH UL1TR000451, UL1RR024982, NCRR/NIH 1UL1RR025780, NCRR/NIH M01RR00071, 1UL1RR024156, NCRR/NIH 5M01RR020359-04, NCRR/NIH UL1RR031988, UL1TRG01422, CTSA Grant UL1RR025741, CTSA Grant UL1TR000150, CTSA Grant UL1TR001422, NIH/NCATS Colorado CTSA UL1 TR002535, NCATS/NIH UL1TR001876, and NIH/CTSA 5UL1TR001425-03). In the ICATA study, Novartis Pharmaceuticals provided the study drug, under a clinical trial agreement with the University of Wisconsin–Madison, Dey Pharma (EpiPens), and SC Johnson (household pest control). None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication. PJG, AT, SMS, and LMW's co-authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency of the US Government..
Publisher Copyright:
© 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2023/1
Y1 - 2023/1
N2 - Background: Asthma prevalence and severity have markedly increased with urbanisation, and children in low-income urban centres have among the greatest asthma morbidity. Outdoor air pollution has been associated with adverse respiratory effects in children with asthma. However, the mechanisms by which air pollution exposure exacerbates asthma, and how these mechanisms compare with exacerbations induced by respiratory viruses, are poorly understood. We aimed to investigate the associations between regional air pollutant concentrations, respiratory illnesses, lung function, and upper airway transcriptional signatures in children with asthma, with particular focus on asthma exacerbations occurring in the absence of respiratory virus. Methods: We performed a retrospective analysis of data from the MUPPITS1 cohort and validated our findings in the ICATA cohort. The MUPPITS1 cohort recruited 208 children aged 6–17 years living in urban areas across nine US cities with exacerbation-prone asthma between Oct 7, 2015, and Oct 18, 2016, and monitored them during reported respiratory illnesses. The last MUPPITS1 study visit occurred on Jan 6, 2017. The ICATA cohort recruited 419 participants aged 6–20 years with persistent allergic asthma living in urban sites across eight US cities between Oct 23, 2006, and March 25, 2008, and the last study visit occurred on Dec 30, 2009. We included participants from the MUPPITS1 cohort who reported a respiratory illness at some point during the follow-up and participants from the ICATA cohort who had nasal samples collected during respiratory illness or at a scheduled visit. We used air quality index values and air pollutant concentrations for PM2·5, PM10, O3, NO2, SO2, CO, and Pb from the US Environmental Protection Agency spanning the years of both cohorts, and matched values and concentrations to each illness for each participant. We investigated the associations between regional air pollutant concentrations and respiratory illnesses and asthma exacerbations, pulmonary function, and upper airway transcriptional signatures by use of a combination of generalised additive models, case crossover analyses, and generalised linear mixed-effects models. Findings: Of the 208 participants from the MUPPITS1 cohort and 419 participants from the ICATA cohort, 168 participants in the MUPPITS1 cohort (98 male participants and 70 female participants) and 189 participants in the ICATA cohort (115 male participants and 74 female participants) were included in our analysis. We identified that increased air quality index values, driven predominantly by increased PM2·5 and O3 concentrations, were significantly associated with asthma exacerbations and decreases in pulmonary function that occurred in the absence of a provoking viral infection. Moreover, individual pollutants were significantly associated with altered gene expression in coordinated inflammatory pathways, including PM2·5 with increased epithelial induction of tissue kallikreins, mucus hypersecretion, and barrier functions and O3 with increased type-2 inflammation. Interpretation: Our findings suggest that air pollution is an important independent risk factor for asthma exacerbations in children living in urban areas and is potentially linked to exacerbations through specific inflammatory pathways in the airway. Further investigation of these potential mechanistic pathways could inform asthma prevention and management approaches. Funding: National Institutes of Health, National Institute of Allergy and Infectious Diseases.
AB - Background: Asthma prevalence and severity have markedly increased with urbanisation, and children in low-income urban centres have among the greatest asthma morbidity. Outdoor air pollution has been associated with adverse respiratory effects in children with asthma. However, the mechanisms by which air pollution exposure exacerbates asthma, and how these mechanisms compare with exacerbations induced by respiratory viruses, are poorly understood. We aimed to investigate the associations between regional air pollutant concentrations, respiratory illnesses, lung function, and upper airway transcriptional signatures in children with asthma, with particular focus on asthma exacerbations occurring in the absence of respiratory virus. Methods: We performed a retrospective analysis of data from the MUPPITS1 cohort and validated our findings in the ICATA cohort. The MUPPITS1 cohort recruited 208 children aged 6–17 years living in urban areas across nine US cities with exacerbation-prone asthma between Oct 7, 2015, and Oct 18, 2016, and monitored them during reported respiratory illnesses. The last MUPPITS1 study visit occurred on Jan 6, 2017. The ICATA cohort recruited 419 participants aged 6–20 years with persistent allergic asthma living in urban sites across eight US cities between Oct 23, 2006, and March 25, 2008, and the last study visit occurred on Dec 30, 2009. We included participants from the MUPPITS1 cohort who reported a respiratory illness at some point during the follow-up and participants from the ICATA cohort who had nasal samples collected during respiratory illness or at a scheduled visit. We used air quality index values and air pollutant concentrations for PM2·5, PM10, O3, NO2, SO2, CO, and Pb from the US Environmental Protection Agency spanning the years of both cohorts, and matched values and concentrations to each illness for each participant. We investigated the associations between regional air pollutant concentrations and respiratory illnesses and asthma exacerbations, pulmonary function, and upper airway transcriptional signatures by use of a combination of generalised additive models, case crossover analyses, and generalised linear mixed-effects models. Findings: Of the 208 participants from the MUPPITS1 cohort and 419 participants from the ICATA cohort, 168 participants in the MUPPITS1 cohort (98 male participants and 70 female participants) and 189 participants in the ICATA cohort (115 male participants and 74 female participants) were included in our analysis. We identified that increased air quality index values, driven predominantly by increased PM2·5 and O3 concentrations, were significantly associated with asthma exacerbations and decreases in pulmonary function that occurred in the absence of a provoking viral infection. Moreover, individual pollutants were significantly associated with altered gene expression in coordinated inflammatory pathways, including PM2·5 with increased epithelial induction of tissue kallikreins, mucus hypersecretion, and barrier functions and O3 with increased type-2 inflammation. Interpretation: Our findings suggest that air pollution is an important independent risk factor for asthma exacerbations in children living in urban areas and is potentially linked to exacerbations through specific inflammatory pathways in the airway. Further investigation of these potential mechanistic pathways could inform asthma prevention and management approaches. Funding: National Institutes of Health, National Institute of Allergy and Infectious Diseases.
UR - http://www.scopus.com/inward/record.url?scp=85145870147&partnerID=8YFLogxK
U2 - 10.1016/S2542-5196(22)00302-3
DO - 10.1016/S2542-5196(22)00302-3
M3 - Article
C2 - 36608946
AN - SCOPUS:85145870147
SN - 2542-5196
VL - 7
SP - e33-e44
JO - The Lancet Planetary Health
JF - The Lancet Planetary Health
IS - 1
ER -